A Study of Drug Combinations Before and After Surgery in People With Gastric, Esophageal, and Gastroesophageal Junction (GEJ) Cancer

Full Title

A Master Protocol for an Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Novel Agents or Combinations as Perioperative Treatment in Participants with Locally Advanced Resectable Gastroesophageal Adenocarcinoma (GEMINI-PeriOp GC)

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Yelena Janjigian’s office at 646-888-4286.

Protocol

25-307

Phase

Phase II (phase 2)

Investigator

Co-Investigators

ClinicalTrials.gov ID

NCT07069712